Patent Application
20170182157
This application claims priority from prior Japanese Patent Application No. 2015-255012, filed on Dec. 25, 2015, entitled “IMMUNOSTIMULATOR AND METHOD FOR PRODUCING THE SAME”, the entire contents of which are incorporated herein by reference.
The present invention relates to an immunostimulator containing virus-like particles, a method for producing the same and a method for potentiating immune effect of a living body by administering the immunostimulator.
For protection against infection by pathogens (infection prevention) and treatment of diseases such as infections and cancer, a vaccine is sometimes administered to a living body. A vaccine is usually administered with an immunostimulator. The immunostimulator is also called as an adjuvant. The immunostimulator has an ability to enhance the effect of vaccine such as enhancement of immune response to a vaccine antigen. For example, US Patent Application Publication No. 2015-174223 describes that an adjuvant can be contained in a pharmaceutical composition containing a peptide vaccine. As specific examples of adjuvant, aluminum phosphate, aluminum hydroxide and the like are described.
The scope of the present invention is defined solely by the appended claims, and is not affected to any degree by the statements within this summary.
The present inventors have unexpectedly found that virus-like particles having an outer coat of SV40 have a property as an adjuvant, thereby completing the present invention.
More specifically, an immunostimulator comprising virus-like particles is provided. The virus-like particles contain an outer coat protein comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 26, SEQ ID No. 33, SEQ ID No. 35, SEQ ID No. 37, SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 and SEQ ID No. 45. The outer coat protein constitutes an outer coat of the virus-like particles. The virus-like particles do not substantially contain a genome DNA of SV40.
An immunostimulator of a present embodiment contains virus-like particles having an outer coat constituted from an outer coat protein derived from SV40 (Simian Virus 40). The phrase “an outer coat is constituted from an outer coat protein” means that the outer coat substantially comprises the outer coat protein. More specifically, the outer coat may be constituted only by an outer coat protein. Alternatively, the outer coat protein may be constituted by an outer coat protein and a protein bindable to the outer coat protein in a range in which the structure of outer coat is maintained. More specifically, the outer coat of wild-type SV40 virus is constituted by assembling of 72 VP1 pentamer units, and VP2 and VP3 are bound to the inside of the constituted outer coat as lining. However, VP1 of SV40 can constitute an outer coat by itself even without VP2 and VP3. In the present embodiment, the outer coat protein means a protein capable of substantially constituting an outer coat by themselves like SV40 VP1.
The outer coat of the virus-like particles preferably does not substantially contain VP2, VP3, or both of them. The phrase “The outer coat of the virus-like particles does not substantially contain VP2, VP3, or both of them” does not eliminate the possibility that VP2 or VP3 is contained in the outer coat of the virus-like particles, but is used as an expression which remains the possibility that VP2 and VP3 are present as a member non-essential for outer coat formation, in a form that the original functions of VP2 and VP3 in a wild-type SV40 cannot be exhibited. The outer coat of the virus-like particles more preferably does not contain both VP2 and VP3.
SV40 is a type of virus belonging to the genus Polyomavirus (Genus: Polyomavirus), in the virus classification published by International Committee on Taxonomy of Viruses (ICTV) in 2014. In the virus classification, reorganization of the classification and modification of generic name, species name or the like are often made. Accordingly, while the classification can be reorganized, or the generic name, species name or the like can be modified in the classification by ICTV or an equivalent academic authority in the future, viruses corresponding to SV40 in the ICTV classification in 2014 are defined to be naturally included in SV40 referred in this specification.
The outer coat protein is not required to have completely same amino acid sequence as that of a wild-type virus. The amino acid sequence may be varied as long as it does not hinder outer coat formation. Variation of amino acid sequence means that one or more amino acid residues are substituted, deleted or added as compared to the wild-type sequence. The variant amino acid sequence has preferably at least 85%, more preferably at least 90% and further preferably at least 95% sequence identity with the amino acid sequence of the wild-type SV40VP1 (SEQ ID No. 1). The outer coat protein may form an outer coat by its self-assembling ability, or may form an outer coat by the action of factors inherent in a host. The outer coat protein may form an outer coat, as monomers, or may form outer coat-forming units (capsomere) constituted from multimers and form an outer coat by assembling of the units. The outer coat protein forms an outer coat by assembling of preferably dimers to decamers and more preferably trimers to pentamers of about 50 to 500 capsomeres. The outer coat protein may be an extracted and purified natural protein, or may be artificially synthesized by a genetic engineering technique or the like.
The outer coat protein contains an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 26, SEQ ID No. 33, SEQ ID No. 35, SEQ ID No. 37, SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 and SEQ ID No. 45. SEQ ID No. 1 is an amino acid sequence of VP1 of the wild-type SV40 VP1 (wt SV40 VP1). SEQ ID No. 1 is encoded by a nucleic acid sequence of SEQ ID No. 2 or SEQ ID No. 25. SEQ ID No. 26 is one of the amino acid sequences of a variant-type SV40 VP1. SEQ ID No. 26 is encoded by a nucleic acid sequence of SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31, or SEQ ID No. 32. SEQ ID No. 33, SEQ ID No. 35, SEQ ID No. 37, SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 and SEQ ID No. 45 are each one of the amino acid sequences of a variant-type SV40 VP1, and are each encoded by a nucleic acid sequence of SEQ ID No. 34, SEQ ID No. 36, SEQ ID No. 38, SEQ ID No. 40, SEQ ID No. 42, SEQ ID No. 44 or SEQ ID No. 46.
The virus-like particles do not substantially contain a genome DNA of SV40. The phrase “do not substantially contain a genome DNA of SV40” means that DNA functioning for self-replication of SV40 is not contained. The virus-like particles do not substantially contain a genome DNA of SV40. Thus, the virus-like particles cannot parasitize a host cell to carry out self-replication like natural virus. The virus-like particles may contain at least part of the genome DNA of SV40, as long as the genome DNA does not function for self-replication.
The shape of outer coat is not particularly limited. The shape may be spherical or tubular. The shape of outer coat is, for example, approximately spherical, regular octahedron to regular icosahedron. VP1 of the wild-type SV40 forms an outer coat of approximately spherical regular icosahedron. Particularly when there is a variation in the amino acid sequence of the outer coat protein, VP1 may have a different shape from the outer coat of the wild-type.
When the outer coat is constituted from monomers of outer coat protein, the number of monomers constituting one outer coat is not particularly limited, but is preferably 100 to 1000 and more preferably 150 to 500. When the outer coat is constituted from capsomeres, the number of capsomeres constituting one outer coat is preferably 50 to 390 and more preferably 72 to 260. VP1 of the wild-type SV40 forms an outer coat by assembly of 72 capsomeres constituted from pentameric VP1 (the number of monomers of 360). Particularly when there is a variation in the amino acid sequence of the outer coat protein, VP1 may constitute an outer coat in a different form from the wild-type.
The diameter of outer coat is not particularly limited. The diameter of outer coat is preferably 30 to 300 nm and more preferably 45 to 200 nm. The diameter of the outer coat of the wild-type SV40 is about 45 nm. Particularly when there is a variation in the amino acid sequence of the outer coat protein, SV40 may have a different diameter from the wild-type.
The outer coat may be constituted from any one kind of the wild-type VP1 and variant-type VP1 described above. Alternatively, the outer coat may contain plural kinds.
The virus-like particles can be used as an adjuvant for administering with an antigen for vaccine, in a vaccine for preventing or treating viral diseases or prevention or treatment of various cancers. Specifically, virus-like particles can be used as an adjuvant for administering with an antigen for vaccine, in the prevention or treatment of diseases such as infections (influenza, immunodeficiency syndrome, hepatitis C, etc.), cancers (cervical cancer, pharyngeal papilloma, etc.), verrucas (verruca vulgaris, inclusion body of verruca vulgaris, verruca plana, etc.), HPV-associated epidermoid cyst, epidermodysplasia verruciformis, condyloma acuminatum and bowenoid papulosis.
When virus-like particles are administered to a living body with an antigen, the virus-like particles can potentiate an immune effect of a living body on the antigen. Namely, virus-like particles of the present embodiment can be used as an adjuvant for administering with an antigen for vaccine, in prevention and/or treatment of diseases such as viral infections, bacterial infections, and cancers. The action mechanism of adjuvant is diverse and is not often elucidated. As one commonly accepted view, it is known that the adjuvant itself has antigenicity and consequently enhances the induction ability of immune cells, thus potentiates an immune effect on the antigen administered together. It has been so far considered that SV40 has low or no immunogenicity since SV40 does not induce increase in expression of CD86 (Cluster of Differentiation) molecule that is an immune activation marker, in a dendritic cell that is representative of antigen-presenting cells. It has been considered that there is no adjuvant effect to a dendritic cell as well, also for general polyomavirus. However, the present inventors have unexpectedly found that, when the virus-like particles of the present embodiment themselves have an antigenicity and administered with an antigen, the virus-like particles potentiate an immune effect on the antigen. It is possible that the virus-like particles of the present embodiment also potentiate an immune effect on the antigen administered together, attributed to the antigenicity of itself. The present inventors have unexpectedly found knowledge that the virus-like particles of the present embodiment potentiate an immune effect of a living body on the antigen administered together, on the contrary to the technical common knowledge so far.
The above antigen may be added to the outer coat protein of the virus-like particles. In the outer coat protein, a site to which the antigen is added is not particularly limited, and the antigen may be added to any amino acid. The antigen may be added in a form of being exposed outside of the outer coat. The antigen may be added in a form of being included in the outer coat.
The kind of antigen is not particularly limited, and examples thereof include polypeptides, sugar chains, nucleic acids, lipids, and the like. The outer coat protein is not included in “antigen” in this specification. The antigen is preferably polypeptide, and more preferably a polypeptide derived from a pathogen. Examples of the polypeptide antigen derived from a pathogen include HA, NA, M1, M2, NP, NS1, NS2, PA, PB1, PB2, PB1-F2 and the like of influenza viruses, Gag, Pol, Env, Tat, Nef, Rev and the like of HIV, E1, E2, Core, NS2, NS3, NS4, NS5 and the like of hepatitis C viruses (HCV), E6, E7 and the like of viruses belonging to the Papillomavirus family, Melan-A/MART-1, gp100, MAGEA3, MAGE-A10, CEA, HER2/new, NY-E50-1, WT-1, hTERT and the like that are proteins specific to cancer cells, and the like. Among them, M1, NP, NS1, PA, PB1 and PB2 of influenza viruses, HER2/new, WT-1 and MAGE-A3 that are proteins specific to cancer cells and the like are preferred. The size of the polypeptide antigen is not particularly limited. The polypeptide antigen may be a full-length protein. The polypeptide antigen may be a part of protein at least containing epitope.
The method of adding an antigen to an outer coat peptide is not particularly limited, and a method known to a person skilled in the art, for example, a chemical procedure, a method using a gene recombination technique and the like can be used. Examples of the chemical procedure include crosslinking by one or more crosslinkers known to a person skilled in the art and the like. Examples of the method using a gene recombination technique include fusing of a gene encoding an antigen and/or antigen epitope (T-helper epitope, CTL epitope, antibody epitope, ADCC (Antibody-dependent cell-mediated cytotoxicity) epitope, etc., epitope inducing immune response) to a gene encoding VP1 of SV40 virus like US Patent Application Publication No. 2014-0286978, and the like. In the present embodiment, an antigen and/or antigen epitope can be specifically added by crosslinking via EDC crosslinker (for example, Thermo Fisher Scientific Inc., etc.).
The schematic view of an example of a virus-like particle is shown in
The virus-like particles potentiate an immune effect of a living body. The phrase “potentiate an immune effect” refers to enhance an immune response to an antigen. Enhancement of immune response refers to, for example, enhancement of the production of cytotoxic T lymphocytes (CTL) induced by administration of an antigen specific to the antigen (enhancement of cellular immunity), enhancement of the production of antibody induced by administration of an antigen specific to the antigen (enhancement of humoral immunity), and the like.
In one embodiment, virus-like particles can potentiate an immune effect, with CD86 expression induction in lymphocytes, particularly, CD4+T cells, CD8+T cells and B cells. For example, CD86 is a protein present in the surface of an antigen-presenting cell (B cell, macrophage, dendritic cell). CD86 is involved in the activation of T cells. CD86 is also an antigen that activates B cells. Accordingly, it is considered that the virus-like particles of the present embodiment activate T cells and B cells with CD86 expression induction, and potentiate an immune effect of a living body.
In the preferred embodiment, virus-like particles can potentiate an immune effect, with CD86 expression in lymphocytes of mouse, dependently on GM1, a type of gangliosides. Gangliosides are present in a lipid bilayer. Gangliosides are involved in adjustment of cellular signal transduction. Accordingly, it is considered that the virus-like particles of the present embodiment activate T cells and B cells, and potentiate an immune effect of a living body, while GM1 is involved in some form in the process of cellular signal transduction to induce CD86 expression.
In another embodiment, virus-like particles induce expression of various CD molecules, specifically, CD69, CD81, CD83, CD196, CD197, CD63, and CD68, in lymphocytes. Thus, the virus-like particles of the present embodiment potentiate an immune effect of a living body.
In another embodiment, virus-like particles do not much induce secretion of inflammatory cytokines involved in the formation of pathological conditions of systemic inflammation, for example, interferon γ (IFN-γ), tumor necrosis factor α (TNF-α), interleukin 6 (IL-6) and interleukin 10 (IL-10), in lymphocytes. On the other hand, virus-like particles induce secretion of chemokines involved in the formation of pathological conditions of local inflammation, for example, CCL3 and CCL4. When a vaccine is administered, the applied part is inflamed, macrophages aggregate, and the antigen is likely to be phagocytosed. Accordingly, antigen presentation effectively occurs. However, it becomes unwanted side effects for a living body when inflammation spreads throughout the whole body. It is considered that the virus-like particles of the present embodiment reduce induction of inflammatory cytokines involved in systemic inflammation and induce chemokines involved in local inflammation, thus effectively potentiate an immune effect of a living body, and side effects are reduced.
In another embodiment, virus-like particles increase phosphorylation of various kinases, specifically, Erk1/2, JNK and p38MAPK, in lymphocytes. Thus, it is considered that the virus-like particles of the present embodiment potentiate an immune effect of a living body.
An immunostimulator may contain any one kind or plural kinds of virus-like particles constituted by VP1 of SEQ ID No. 1, virus-like particles constituted by VP1 of SEQ ID No. 26, virus-like particles constituted by VP1 of SEQ ID No. 33, virus-like particles constituted by VP1 of SEQ ID No. 35, virus-like particles constituted by VP1 of SEQ ID No. 37, virus-like particles constituted by VP1 of SEQ ID No. 39, virus-like particles constituted by VP1 of SEQ ID No. 41, virus-like particles constituted by VP1 of SEQ ID No. 43, and virus-like particles constituted by VP1 of SEQ ID No. 45, as long as it is pharmacologically effective.
In the immunostimulator, virus-like particles may be formulated with an antigen and/or a pharmaceutical additive known to a person skilled in the art. The pharmaceutical additive as described above is not particularly limited, and examples thereof include excipients, lubricants, binders, disintegrants, coating agents, capsule base materials, plasticizers, colorants, solvents, stabilizers, preservatives, buffers, analgesics, bases, emulsifiers and suspending agents, other corrigents, sweeteners, absorbents, dissolution adjuvants, pH adjusting agents, thickeners, tonicity agents, dispersants, antiseptics, wetting agents, flavoring agents, antioxidants, and the like.
The excipient is not particularly limited, and examples thereof include mannitol, sucrose, glucose, corn starch, crystalline cellulose, calcium hydrogen phosphate, and the like.
The lubricant is not particularly limited, and examples thereof include magnesium stearate, talc, colloidal silica, and the like.
The binder is not particularly limited, and examples thereof include gum arabic, hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), methylcellulose (MC), povidone (PVP), polyvinyl alcohol (PVA), and the like.
The disintegrant is not particularly limited, and examples thereof include cross-linked carmellose sodium, carmellose calcium, cross-linked povidone, sodium carboxymethyl starch, and the like.
The coating agent is not particularly limited, and examples thereof include coating agents for sugar coating such as sucrose and talc, enteric coating agents such as carboxymethylethyl cellulose, gastrosoluble coating agents such as polyvinyl acetal diethyl aminoacetate, and the like.
The capsule base material is not particularly limited, and examples thereof include gelatin and the like.
The plasticizer is not particularly limited, and examples thereof include triacetin, medium-chain triglyceride, and the like.
The colorant is not particularly limited, and examples thereof include edible tar colors, lake pigments, iron sesquioxide, and the like.
The solvent is not particularly limited, and examples thereof include aqueous solvents such as water for injection and sterile purified water, nonaqueous solvents such as vegetable oils (including olive oil, soybean oil, sesame oil and the like), and the like.
The stabilizer is not particularly limited, and examples thereof include inert gas such as nitrogen and carbon dioxide, chelating agents such as EDTA, reduction substrates such as L-ascorbic acid, and the like.
The preservative is not particularly limited, and examples thereof include p-oxybenzoic ester, chlorobutanol, and the like.
The buffer is not particularly limited, and examples thereof include sodium salts of citric acid, acetic acid, phosphoric acid, and the like.
The analgesic is not particularly limited, and examples thereof include benzyl alcohol, procaine hydrochloride, glucose, and the like.
The base is not particularly limited, and examples thereof include bases for suppositories such as cacao butter and gelatin, bases for ointments such as liquid paraffin and carnauba wax, and the like.
The emulsifier is not particularly limited, and examples thereof include gum arabic, polysorbate, sodium lauryl sulfate, and the like.
The suspending agent is not particularly limited, and examples thereof include gum arabic, sodium alginate, tragacanth, aluminum monostearate, and the like.
An immunostimulator may be any of a solid preparation, a semisolid preparation, a liquid preparation, an injection, a suppository, and other preparation form known to a person skilled in the art. Specific dosage form is not particularly limited, and examples thereof include tablets, pills, granules, powders, capsules, troches, injections, liquid agents, elixirs, syrups, limonades, suppositories, ointments, suspension agents, emulsions, liniments, lotions, percutaneous absorption preparations, patches, cataplasms, aerosols, and the like.
The liquid preparation is prepared, for example, by extracting virus-like particles from a host cell expressing the virus-like particles, and adding an antigen and diluting the virus-like particles with an appropriate solvent as necessary.
The suspension agent is prepared, for example, by producing a homogenate obtained by homogenizing a host cell expressing the virus-like particles, and adding an antigen, and extracting, purifying, and diluting the homogenate with a solvent as necessary. Specifically, when a lepidopterous insect individual such as a silkworm is used as a host, a suspension agent can be prepared by grinding an individual expressing the virus-like particles, and roughly purifying the ground individual.
When the virus-like particles are not formulated with an antigen, an immunostimulator containing the virus-like particles may be administered simultaneously with an antigen, or may be separately administered. The virus-like particles are preferably administered simultaneously with an antigen. For example, an immunostimulator is mixed with an antigen or a composition containing an antigen, and administered to a living body. Regarding virus-like particles, the phrase “administered with an antigen” does not necessarily mean that virus-like particles must be administered at the same time points, but is used as an expression including that both antigen and virus-like particles are administered at separate time points in one dosage schedule.
The administration route of an immunostimulator is not particularly limited, and examples thereof include transmucosal administration (for example, oral administration, transnasal administration, intranasal administration, buccal administration, enema administration, and the like), parenteral administration (for example, intraperitoneal injection, subcutaneous injection, intravenous injection, intramuscular injection, injection into a space between tissues, and the like), transdermal administration, and the like. More specifically, the immunostimulator of the present embodiment can be used by not only a high burden administration by injection or the like, but also a low burden administration by oral ingestion, administration by collunarium, enema or the like. For example, an immunostimulator can be used as an adjuvant for a vaccine for animals by mixing into animal feed with an antigen.
The dose and number of doses of an immunostimulator can be properly set by a person skilled in the art according to the kind of an antigen, animal species of an administration target, and symptom, age, body weight, administration form and the like, of an administration target. The dose is usually 0.01 μg to 100 mg, preferably 0.1 μg to 50 mg, and more preferably 1.0 μg to 10 mg, and it is preferred to administer an immunostimulator once per few days to few months.
The administration target of an immunostimulator can be biological bodies, more specifically, human or animals other than human (mammals other than human, birds, reptiles, and the like). Examples of animals other than human include bovine, equine, porcine, chicken, canine, feline, mouse, rat, lagomorph, simian, and the like.
The immunostimulator of the present embodiment contains a pharmacologically effective amount of virus-like particles from the viewpoint of immune effect enhancement. The virus like particles may cause a pharmaceutically acceptable side effect when administered, but it is preferred for the animal of an administration target that there is no pathogenicity, and a side effect is not caused.
The immunostimulator of the present embodiment can be produced by preparing virus-like particles according to a method known to a person skilled in the art, and formulating the virus-like particles by mixing with an antigen and/or a pharmaceutically acceptable excipient or the like as necessary.
The virus-like particles can be prepared using an outer coat protein containing an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 26, SEQ ID No. 33, SEQ ID No. 35, SEQ ID No. 37, SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 and SEQ ID No. 45. For example, it can be performed by dispersing an outer coat protein in a proper medium. The medium and dispersion conditions can be properly set by a person skilled in the art.
Before preparing virus-like particles, the outer coat protein may be obtained by incorporating a DNA encoding the outer coat protein incorporated into a host cell to express the outer coat protein in the host cell. These proteins can be obtained by a method known to a person skilled in the art, for example, gene recombination and the like.
The host cell is not particularly limited as long as it does not hinder the formation of virus-like particles. The host cell is selected, for example, from a group consisting of insect cells (including insect individuals such as silkworm), Escherichia coli, yeasts and plants. The host cell is preferably an insect cell, more preferably a lepidopterous insect individual, and further preferably a silkworm.
When an outer coat protein is expressed in a host cell, virus-like particles may be prepared by contact of the outer coat proteins expressed in the host cell each other. Alternatively, virus-like particles may be formed in a production process such as homogenization, purification and extraction on the host cell.
The virus-like particles formed in the host cell may be collected as necessary. Collection method is not particularly limited, but a person skilled in the art can properly selected mainly depending on the kind of the host cell. For example, when the host cell is an insect cell, an Escherichia coli cell or the like, cytolysis and the like by ultrasonication or the like can be used. When the host cell is a pupa of a lepidopterous insect, a method of eluting virus-like particles by grinding or the like, and collecting a supernatant after centrifugation can be used.
In a preferred embodiment, first, an insect cell or insect individual is infected with a baculovirus into which a DNA encoding an outer coat protein is incorporated. Next, the insect cell or insect individual is subjected to ultrasonic treatment or ground, then centrifuged or filtered, and the supernatant is collected, whereby virus-like particles can be obtained.
The virus-like particles may be purified as necessary. The purification method is not particularly limited, and examples thereof include methods known to a person skilled in the art such as density gradient centrifugation and chromatography and the like.
An antigen may be added to the virus-like particles. A method of adding an antigen to an outer coat peptide is as described above.
Formulation can be performed, for example, by mixing virus-like particles to which an antigen is added with an appropriate pharmaceutical composition, or mixing virus-like particles with an antigen and/or an appropriate pharmaceutical additive, molding into a desired dosage form, and coating the dosage form as necessary.
Specifically, when a dosage form is formed into a solid preparation, for example, a tablet, it can be formulated, for example, by mixing virus-like particles to which an antigen is added with an appropriate excipient, binder and/or disintegrant, or mixing virus-like particles with an antigen and/or an appropriate excipient, binder and/or disintegrant, adding an appropriate lubricant, further mixing the ingredients, tableting the mixture, and coating the dosage form as necessary.
When a dosage form is formed into an injection or a liquid preparation, it can be formulated, for example, by dispersing virus-like particles to which an antigen is added or virus-like particles in an appropriate solvent, adding an antigen and/or filtering or sterilizing the dispersion as necessary, and filling the dispersion in a predetermined container.
When a dosage form is formed into an ointment, it can be formulated, for example, by melting an appropriate ointment in a mixer equipped with a warming device, stopping warming, mixing at a low speed until it coagulates in the form of an ointment, adding virus-like particles to which an antigen is added or virus-like particles and an antigen as necessary, immediately before coagulation, and filling the mixture in a predetermined container.
When a dosage form is formed into a suppository, it can be formulated, for example, by mixing virus-like particles to which an antigen is added with an appropriate base for suppositories previously melted at a low temperature, or mixing virus-like particles with an appropriate base for suppositories previously melted at a low temperature, and an antigen as necessary, pouring the mixture into a mold, and cooling it to harden.
Another embodiment relates to virus-like particles for potentiating an immune effect of a living body. More specifically, another embodiment relates to virus-like particles for potentiating an immune effect of a living body, in which the virus-like particles contain an outer coat protein containing an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 26, SEQ ID No. 33, SEQ ID No. 35, SEQ ID No. 37, SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 and SEQ ID No. 45, the outer coat protein constitutes an outer coat of the virus-like particles, and the virus-like particles do not substantially contain a genome DNA of SV40.
The virus-like particles, outer coat protein, outer coat and the like are as described above.
The virus-like particles of the present embodiment can be used as an immunostimulator that potentiates an immune effect of a living body on an antigen by administering the virus-like particles with the antigen, in the prevention or treatment of disease. More specifically, the virus-like particles can be used as an immunostimulator that potentiates an immune effect of a living body on an antigen by administering the virus-like particles with the antigen, in the prevention or treatment of diseases such as infections (influenza, HIV, hepatitis C, etc.), cancers (cervical cancer, pharyngeal papilloma, etc.), verrucas (verruca vulgaris, inclusion body of verruca vulgaris, verruca plana, etc.), HPV-associated epidermoid cyst, epidermodysplasia verruciformis, condyloma acuminatum and bowenoid papulosis.
Accordingly, it can be also said that another embodiment relates to virus-like particles for treating a disease by administering the virus-like particles with the antigen. More specifically, the present embodiment relates to virus-like particles for treating a disease by administering the virus-like particles with an antigen, in which the virus-like particles contain an outer coat protein containing an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 26, SEQ ID No. 33, SEQ ID No. 35, SEQ ID No. 37, SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 and SEQ ID No. 45, the outer coat protein constitutes an outer coat of the virus-like particles, and the virus-like particles do not substantially contain a genome DNA of SV40.
The virus-like particles, outer coat protein, outer coat, antigen, diseases and the like are as described above.
Another embodiment relates to a method for potentiating an immune effect of a living body including administering virus-like particles to the living body. The virus-like particles contain an outer coat protein containing an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 26, SEQ ID No. 33, SEQ ID No. 35, SEQ ID No. 37, SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 and SEQ ID No. 45, the outer coat protein constitutes an outer coat of the virus-like particles, and the virus-like particles do not substantially contain a genome DNA of SV40.
The virus-like particles, outer coat protein, outer coat and administration method thereof, a biological body and the like are as described above.
It can be also said that another embodiment relates to a method for preventing or treating diseases including administering virus-like particles to a living body. More specifically, the present embodiment relates to a method for preventing or treating diseases, including administering virus-like particles to a living body with an antigen, in which the virus-like particles contain an outer coat protein containing an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 26, SEQ ID No. 33, SEQ ID No. 35, SEQ ID No. 37, SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 and SEQ ID No. 45, the outer coat protein constitutes an outer coat of the virus-like particles, and the virus-like particles do not substantially contain a genome DNA of SV40.
The virus-like particles, outer coat protein, outer coat, antigen and administration method thereof, a biological body, diseases and the like are as described above.
Another embodiment relates to use of virus-like particles in the production of an immunostimulator.
The virus-like particles, outer coat protein, outer coat, immunostimulator and administration method thereof, a biological body, diseases and the like are as described above.
Hereinbelow, the present invention will be described in detail by way of examples, but the present invention is not limited to these examples.
Escherichia coli DH10bac (invitrogen) holding a baculovirus genome was transformed with a plasmid obtained by inserting wt SV40 VP1 gene (SEQ ID No. 2; the amino acid sequence is shown in SEQ ID No. 1) into Sal I site and Kpn I site of pFastBac1 plasmid (invitrogen) to prepare a recombinant baculovirus genome into which VP1 was incorporated. The recombinant baculovirus genome was transfected to Sf-9 cells. After three days, the supernatant thereof was collected to obtain a solution containing recombinant baculovirus. A part of this solution was again infected with Sf-9 cells (invitrogen), thereby increasing a recombinant baculovirus titer. The resulting solution was referred to as a stock solution of a recombinant baculovirus.
A recombinant baculovirus with wt SV40 VP1 incorporated therein was infected in a 15 cm culture dish in which 3×107 Sf-9 cells were inoculated at a multiplicity of infection of 0.05 to 0.2 (M.O.I. base). A total of 10 dishes was each prepared. Three days after infection, a total of 3×108 Sf-9 cells inoculated on these 10 dishes were collected, and washed with PBS(−). Thereafter, the cells were resuspended in 10 ml of a buffer for VP1 ultrasonic treatment (20 mM Tris-HCl (pH 7.9), 1% (w/vol) deoxycholic acid (Sigma)). In order to suppress endogenous protease activity, 2 mM phenylmethylsulfonyl fluoride (final concentration of 2 μM, Sigma), chymostatin (final concentration of 1 μg/ml, Sigma), aprotinin (final concentration of 1 μg/ml, Sigma), leupeptin (final concentration of 1 μg/ml, Sigma), antipain (final concentration of 1 μg/ml, Sigma) and pepstatin (final concentration of 1 μg/ml, Sigma) were added thereto, and the mixture was ultrasonically crushed. Thereafter, the crushed substance was centrifuged at 15,000 rpm, 4° C. for 5 minutes to separate into supernatant and pellet, and the supernatant was defined as a lysate solution.
Each 1.5 ml of a 20% CsCl solution (20 mM Tris-HCl (pH 7.9), 20% (w/vol) cesium chloride), a 30% CsCl solution (20 mM Tris-HCl (pH 7.9), 30% (w/vol) cesium chloride), a 40% CsCl solution (20 mM Tris-HCl (pH 7.9), 40% (w/vol) cesium chloride), and a 50% CsCl solution (20 mM Tris-HCl (pH 7.9), 50% (w/vol) cesium chloride) were superposed in an Ultra-Clear centrifugation tube (14×89 mm, Beckman coulter) in descending order of density, for density gradient centrifugation of cesium chloride. Subsequently, 5 ml of a lysate solution containing wt SV40 VP1 was further superposed. The centrifugation tube was ultracentrifuged at 35,000 rpm, 4° C. for 3 hours (SW41Ti rotor, Beckman).
After ultracentrifugation, a white band appeared at the center was collected with 23 G, 1 ml of a Terumo syringe (0.60×32 mm, TERUMO). This fraction was mixed with a 37% CsCl solution (20 mM Tris-HC (pH 7.9), 37% (w/vol) cesium chloride), and the mixture was transferred to an Ultra-Clear centrifugation tube (11×60 mm, Beckman coulter). Thereafter, the centrifugation tube was ultracentrifuged at 50,000 rpm, 4° C. for 20 hours (SW60Ti rotor, Beckman). After ultracentrifugation, a white band appeared at the center was collected with 23 G, 1 ml of a Terumo syringe (0.60×32 mm, TERUMO). This fraction was dialyzed (Slide-A-Lyzer (trademark) MINI Dialysis Units, 3500 MWCO, Thermo SCIENTIFIC) against a PBS(−) solvent. This fraction was centrifuged at 15,000 rpm, 4° C. for 5 minutes. The supernatant was collected and referred to as a purified VP1 VLP fraction.
Immobilization of FMP:58-66 Peptide on SV40 Wild-Type VP1 VLP
A sample of wt SV40 VP1 VLP in which FMP:58-66 epitope peptide (GILGFVFTL, SEQ ID No. 3; herein also called as “CTL epitope of M1”) was immobilized thereon was prepared, as described below.
(1) 35.04 μl of a MES buffer of the same composition was added to 39.96 μl of wt SV40 VP1 VLP (3752.7 ng/l) dialyzed against a MES buffer (0.1 M MES (2-(N-morpholino)ethanesulfonic acid), 0.9% sodium chloride, pH 4.7, BupH MES buffered saline water pack, 28390, Thermo SCIENTIFIC) to make a total of 75 μl. 32.4 μl of a MES buffer was added to 155.1 μl of 10 mM FMP: 58-66 peptide (GILGFVFTL) (molecular weight of 966.9) dissolved in DMSO to make a total of 187.5 μl. Moreover, these buffers were mixed. Thereto was added 7.5 μl of EDC crosslinker (EDC, 22980, Thermo SCIENTIFIC) (10 mg/ml in redistilled water). Furthermore, 30 μl of redistilled water was added to make a total amount of 300 μl. This mixture liquid was incubated at room temperature for 2 hours to react a crosslinker. This was referred to as a 1:10 (with EDC) sample in a weight ratio of VP1:FMP:58-66 epitope peptide.
(2) 35.04 μl of a MES buffer of the same composition as described above was added to 39.96 μl of SV40 wild type VP1 VLP (3752.7 ng/μl) dialyzed against a MES buffer of the same composition to make a total of 75 μl. 109.95 μl of a MES buffer was added to 77.55 μl of 10 mM FMP:58-66 peptide (GILGFVFTL) (molecular weight of 966.9) dissolved in DMSO to make a total of 187.5 μl. Moreover, these buffers were mixed. Thereto was added 7.5 μl of EDC crosslinker (EDC, 22980, Thermo SCIENTIFIC) (10 mg/ml in redistilled water). Furthermore, 30 μl of redistilled water was added to make a total amount of 300 μl. This mixture liquid was incubated at room temperature for 2 hours to react a crosslinker. This was referred to as a 1:5 (with EDC) sample in a weight ratio of VP1:FMP:58-66 epitope peptide.
(3) 35.04 μl of a MES buffer of the same composition as described above was added to 39.96 μl of SV40 wild type VP1 VLP (3752.7 ng/l) dialyzed against a MES buffer of the same composition to make a total of 75 μl. 148.72 μl of a MES buffer was added to 38.78 μl of 10 mM FMP:58-66 peptide (GILGFVFTL) (molecular weight of 966.9) dissolved in DMSO to make a total of 187.5 μl. Moreover, these buffers were mixed. Thereto was added 7.5 μl of EDC crosslinker (EDC, 22980, Thermo SCIENTIFIC) (10 mg/ml in redistilled water). Furthermore, 30 μl of redistilled water was added to make a total amount of 300 μl. This mixture liquid was incubated at room temperature for 2 hours to react a crosslinker. This was referred to as a 1:2.5 (with EDC) sample in a weight ratio of VP1:FMP:58-66 epitope peptide.
(4) 32.4 μl of a MES buffer was added to 155.1 μl of 10 mM FMP:58-66 peptide (GILGFVFTL) (molecular weight of 966.9) dissolved in DMSO, and the mixture was added to 75 μl of a MES buffer to make a total of 262.5 μl. Moreover, these buffers were mixed. Thereto was added 7.5 μl of EDC crosslinker (EDC, 22980, Thermo SCIENTIFIC) (10 mg/ml in redistilled water). Furthermore, 30 μl of redistilled water was added to make a total amount of 300 μl. This mixture liquid was incubated at room temperature for 2 hours to react a crosslinker. This was referred to as a peptide alone (with EDC) sample.
(5) 35.04 μl of a MES buffer of the same composition as described above was added to 39.96 μl of SV40 wild type VP1 VLP (3752.7 ng/l) dialyzed against a MES buffer of the same composition to make a total of 75 μl. 32.4 μl of a MES buffer was added to 155.1 μl of 10 mM FMP:58-66 peptide (GILGFVFTL) (molecular weight of 966.9) dissolved in DMSO to make a total of 187.5 μl. Then, these buffers were mixed. Thereto was added 37.5 μl of redistilled water to make a total amount of 300 μl. This mixture liquid was incubated at room temperature for 2 hours. This was referred to as a 1:10 (no EDC) sample in a weight ratio of VP1:FMP:58-66 epitope peptide.
(6) 60 μl of a MES buffer of the same composition as described above was added to 15 μl of bovine serum albumin (BSA) (10 μg/μl) dissolved in a MES buffer of the same composition to make a total of 75 μl, as a negative control. 32.4 μl of a MES buffer was added to 155.1 μl of 10 mM FMP:58-66 peptide (GILGFVFTL) (molecular weight of 966.9) dissolved in DMSO to make a total of 187.5 μl. Moreover, these buffers were mixed. Thereto was added 7.5 μl of EDC crosslinker (EDC, 22980, Thermo SCIENTIFIC) (10 mg/ml in redistilled water). Furthermore, 30 μl of redistilled water was added to make a total amount of 300 μl. This mixture liquid was incubated at room temperature for 2 hours to react a crosslinker. This was referred to as a 1:10 (with EDC) sample in a weight ratio of BSA:FMP:58-66 peptide.
1 μl samples of the above (1) to (5) were developed by 10% SDS-PAGE and stained with CBB. 1 μl samples of the above (1) to (5) were developed by 10% SDS-PAGE and then transferred to a PVDF membrane. Western blotting was performed with an anti-SV40 VP1 antibody. The results are shown in
The following experiment used a transgenic mouse using C57BL/6 as a background and expressing a chimera of HLA-A*0201 and H-2Db further fused with human β2m (hereinafter, HHD mouse). This mouse is a β2m and H-2Db knockout mouse, thus it is considered that mouse-derived MHC class I is not exposed to the cell surface.
An 8-week old HHD mouse was immunized with 100 μl of each of the samples of the above (1) to (6) via the intraperitoneal route.
For immunization, a 1 ml syringe with a 27-gauge needle inserted (Myjector, syringe with an injection needle, for insulin, TERUMO, SS-10M2713) was used. After one week from administration, the spleen of the immunized mouse was collected. Lymphocytes were prepared by the following method, and Intra-cellular cytokine staining (ICS) analysis described below was performed.
The spleen was removed from the immunized mouse. The spleen was put in a 96 cm dish with 5 ml of RPMI-1640 medium. The spleen was well loosened in the medium using tweezers, and a solution containing lymphocytes eluted in the medium was transferred to a 15 ml tube. The φ6 cm dish was again washed with 5 ml of RPMI-1640 medium. The supernatant was added to the 15 ml tube so that the total amount was 10 ml. The supernatant was again transferred to a new 15 ml tube, leaving tissue sections deposited at the bottom of the 15 ml tube. The 15 ml tube was centrifuged at 1,200 rpm at room temperature for 5 minutes to obtain a pellet containing lymphocytes. The supernatant was removed, and the pellet was loosened. Thereafter, in order to remove erythrocytes, 250 μl of a NH4Cl-tris solution was added thereto, and the mixture was stirred. Thereafter, 10 ml of RPMI-1640 medium was quickly added thereto, and the 15 ml tube was centrifuged at 1,2000 rpm at room temperature for 5 minutes to obtain a pellet containing lymphocytes. The supernatant was removed, and the pellet was loosened. Thereafter, 10 ml of RPMI-1640 medium was again added thereto. The medium containing lymphocytes was transferred to a new 15 ml tube with a pipette so as not to suck modified erythrocytes as much as possible. The 15 ml tube was again centrifuged at 1,200 rpm at room temperature for 5 minutes. The supernatant was removed, and then the pellet was loosened. The pellet was again suspended in 10 ml of RPMI-1640 medium, and centrifuged at 1,200 rpm at room temperature for 5 minutes. The supernatant was removed, and the pellet was finally suspended in 2 ml of 10% FCS mixing RPMI-1640 medium. In order to count lymphocytes, 10 μl of the above suspension was added to 490 μl of a 2% acetic acid solution. The number of cells was counted with a Burker-Turk hemocytometer. The resulting mixture was diluted with 10% FCS mixing RPMI-1640 medium so as to be 1×107 cells/ml.
After immunizing the mouse, ICS analysis was performed, in order to identify the ratio of CD8 positive IFN-γ positive CTL induced by reacting to FMP:58-66 epitope in the lymphocytes collected from the spleen. BD GolgiPlug (trademark) (BD Biosciences) diluted 25-fold with 10% FCS mixing RPMI-1640 medium was added to a 96-well round-bottom plate, at 5 μl per well. Thereto was further added 100 μl of 20 μM FMP:58-66 epitope (GILGFVFTL, Operon) diluted with 10% FCS mixing RPMI-1640 medium. To this well was added 100 μl of the lymphocytes prepared above. Thereafter, the mixture was incubated at 37° C., 5% CO2, for 5 hours.
After incubation at 4° C., the mixture was spun down at 1,400 rpm to remove the supernatant, and the cells were loosened with a Vortex mixer. Thereafter, FACS buffer (2% FCS, 0.1% sodium azide, 1×PBS(−)) was added at 200 μl per well. The mixture was again spun down at 4° C., 1,400 rpm to remove the supernatant, and the cells were loosened. Thereafter, 100 μl of Mouse BD Fc Block (trademark) (BD Pharmingen) diluted to 5 μg/ml with FACS buffer was added thereto, and the mixture was incubated at 4° C. for 10 minutes.
After incubation, the mixture was again spun down at 4° C., 1,400 rpm to remove the supernatant, and the cells were loosened.
Thereafter, FACS buffer was added at 200 μl/well. The mixture was again spun down at 4° C., 1,400 rpm to remove the supernatant. Washing operation using 200 μl/well of FACS buffer was again carried out.
FITC Rat Anti-Mouse CD8a Clone: 53-6.7 (BD Pharmingen) diluted to 10 μg/ml with FACS buffer was added to the loosened cells, at 50 μl per well. The mixture was incubated in a dark place at 4° C. for 30 minutes.
After incubation, washing operation with 200 μl/well of FACS buffer was carried out twice.
Thereafter, 100 μl of BD Cytofix/Cytoperm (trademark) (BD Biosciences) was added to the loosened cells, at 100 μl per well, and the mixture was incubated in a dark place at 4° C. for 20 minutes. After incubation, the washing operation as same as described above was carried out twice, using 200 μl of 1×BD Perm/Wash (trademark) (BD biosciences) in place of the FACS buffer. Thereafter, 50 μl of PE anti-mouse IFN-γClone: XMG1.2 (BioLegend) diluted to 10 μg/ml with 1×BD Perm/Wash (trademark) was added to the loosened cells. The mixture was incubated in a dark place at 4° C. for 30 minutes.
After incubation, the washing operation as same as described above was carried out twice, using 200 μl of 1×BD Perm/Wash (registered trademark). Thereafter, FACS fixation buffer (1% formaldehyde, 1×FACS buffer) was added to the loosened cells, at 100 μl per well, and the mixture was incubated in a dark place at 4° C. overnight.
After incubation, 400 μl of FACS buffer was added to 5 ml of a polystyrene tube (BD Falcon, 5 ml polystyrene round-bottom tube 12×75 mm style). Thereto was added the sample fixed with 100 μl of FACS fixation buffer. Thereafter, dot plot analysis was performed with FACScan (Becton Dickinson). Cell Quest (Becton Dickinson) software was used for the analysis.
The results of ICS analysis are shown in
Based on these results, the possibility that the induction ability of epitope-specific CTL is high, and VLP is involved in CTL, in the sample containing mouse lymphocytes immunized with VLP with FMP:58-66 epitope immobilized thereon, was suggested. The induction ability of epitope-specific CTL was low even when immobilizing epitope on BSA. Thus, it was suggested that wt SV40 VP1 VLP is necessary for effectively inducing epitope-specific CTL.
In order to show that a CD8 positive intracellular IFN-γ positive cell damages cells, 51Chrome release analysis was performed. Lymphocytes of the spleen of a non-immunized HHD mouse were prepared by the same method as described above. 4 μl of a peptide of 10 mM CTL epitope of M1 (FMP:58-66 peptide; GILGFVFTL; Operon) was added to 2.4×108 spleen lymphocytes of a non-immune mouse in 2 ml of 10% FCS mixing RPMI-1640 medium in a 15 ml tube. The mixture was incubated at 37° C., 5% CO2 incubator, for 2 hours. After incubation, 20 Gy (gray) X ray was irradiated. After irradiation, the 15 ml tube was centrifuged at 1,200 rpm at room temperature for 5 minutes to obtain a pellet containing lymphocytes. The supernatant was removed, and the pellet was loosened. Thereafter, 2 ml of 10% FCS mixing RPMI-1640 medium was added thereto. In order to count lymphocytes, 10 μl of the lymphocyte solution was added to 490 μl of a 2% acetic acid solution. The number of cells was counted with a Burker-Turk hemocytometer. The resulting mixture was diluted with 10% FCS mixing RPMI-1640 medium so as to be 5×106 cells/ml.
On the other hand, 50 μl of a VLP solution (1:10 (with EDC)) with FMP: 58-66 peptide immobilized thereon was immunized by intraperitoneal immunization. After 1 week of immunization, the spleen was removed from the mouse. The spleen was put in a φ6 cm dish each with 5 ml of RPMI-1640 medium. The spleen was well loosened in the medium using tweezers, and a solution containing lymphocytes eluted in the medium was transferred to a 15 ml tube. The φ6 cm dish was again washed with 5 ml of RPMI-1640 medium. The supernatant was added to the 15 ml tube so that the total amount was 10 ml. The blood was not removed from the immunized lymphocytes. Therefore, then the supernatant was again transferred to a new 15 ml tube, leaving tissue sections deposited at the bottom of the 15 ml tube. The 15 ml tube was centrifuged at 1,200 rpm at room temperature for 5 minutes to obtain a pellet containing lymphocytes. The supernatant was removed, and the pellet was loosened. Thereafter, 2 ml of 10% FCS mixing RPMI-1640 medium was added thereto. In order to count lymphocytes, 10 μl of the lymphocyte solution was added to 490 μl of a 2% acetic acid solution. The number of cells was counted with a Burker-Turk hemocytometer. The resulting mixture was diluted with 10% FCS mixing RPMI-1640 medium so as to be 5×106 cells/ml.
In a 48-well plate, 500 μl/well of the above X-ray irradiated non-immune lymphocytes (5×106 cells/ml) after incubated with peptide of M1 CTL epitope and 500 μl/well of the above immunized lymphocytes (5×106 cells/ml) were mixed. 24 wells of this well were prepared per sample. After mixing, the plate was incubated at 37° C., 5% CO2 incubator, for 7 days.
Thereafter, the lymphocytes in the 24 wells were collected in one 50 ml tube. The 15 ml tube was centrifuged at 1,200 rpm at room temperature for 5 minutes to obtain a pellet containing lymphocytes. The supernatant was removed, and the pellet was loosened. Thereafter, 2 ml of 10% FCS mixing RPMI-1640 medium was added thereto. In order to count lymphocytes, 20 μl of the lymphocyte solution was added to 20 μl of a 0.4% Trypan blue solution (Gibco). The number of cells was counted with a Burker-Turk hemocytometer. The resulting mixture was diluted with 10% FCS mixing RPMI-1640 medium or concentrated so as to be 7.5×106 cells/ml. The lymphocytes prepared as described above were referred to as effector cells.
On the other hand, 1 ml each of 1×106 cells/ml RMA-HHD cultured cells was dispensed into two 15 ml tubes. To one tube was added 5 μl of a peptide of 10 mM M1 CTL epitope (GILGFVFTL, Operon). To other tube was not added a peptide. These tubes were each incubated at 37° C., 5% CO2 incubator, for 2 hours. Thereafter, the 15 ml tube was centrifuged at 1,200 rpm at room temperature for 5 minutes to obtain a pellet containing the cells. The supernatant was removed, and the pellet was loosened. Thereafter, 100 μCi (microsievert) of a Na251CrO4 solution was added. The mixture was incubated at 37° C., 5% CO2 incubator, for 30 minutes. Thereafter, the 15 ml tube was centrifuged at 1,200 rpm at room temperature for 5 minutes to obtain a pellet containing the cells. The supernatant was removed, and the pellet was loosened. Thereafter, 1 ml of 10% FCS mixing RPMI-1640 medium was added thereto, for washing operations. The 15 ml tube was centrifuged at 1,200 rpm at room temperature for 5 minutes to form a pellet containing lymphocytes. Then, the supernatant was removed. The washing operations were repeated five times. Finally, after removing the supernatant, 1 ml of 10% FCS mixing RPMI-1640 medium was added thereto. In a new 15 ml tube, 500 μl of this cell solution and 9.5 ml of 10% FCS mixing RPMI-1640 medium were mixed, and the mixture was diluted 20-fold. This diluted cell solution was referred to as a target cell fluid.
Into a 96-well plate was dispensed 100 μl of the target cell fluid (5×103 cells). Thereto was each added 100 dl (7.5×105 cells) of the effector cell fluid, a mixed liquid of 20 μl (1.5×105 cells) of the effector cell fluid and 80 μl of 10%/o FCS mixing RPMI-1640 medium, and a mixed liquid of 10 pd (7.5×104 cells) of the effector cell fluid and 90 μl of 10% FCS mixing RPMI-1640 medium, so that the ratios of effector cells:target cells became 150:1, 30:1, and 15:1, respectively. To 100 μl of the targe cell fluid (5×103 cells) was added 100 μl of a 5% Triton-X 100 solution as a positive control, and 100 μl of a 10% FCS mixing RPMI-1640 medium as a negative control, respectively. After mixing, the plate was incubated at 37° C., 5% CO2 incubator, for 4 hours.
Thereafter, the supernatant was collected using Supernatant collection system (Molecular Devices). The released 51Cr gamma ray was counted and analyzed with AUTO WELL GAMMA SYSTEM (ARC-380CL, Aloka) and ALOKA RIA Program (ARCAS ver. 3.11, Aloka). % Specific lysis was calculated by 100×(count (sample)−count (negative control))/(count (positive control)−count (negative control)).
The result is shown in
The purified VP1 VLP fraction prepared in Example 1 was used as a wt SV40 VP1 VLP solution. To a 96-well flat-bottom plate was added 5 μl of a wt SV40 VP1 VLP solution (500 μg/ml in PBS(−)). Meanwhile, a well to which a wt SV40 VP1 VLP solution was not added was prepared in a round-bottom plate. To a separate flat-bottom plate was added 5 μl of PBS(−) buffer. Meanwhile, a separate well to which PBS(−) buffer was not added was prepared in a round-bottom plate. Thereto were added 5×105 lymphocytes prepared as described in Example 1, except for using the spleen of non-immune HHD mouse in place of that of the intraperitoneally immunized mouse. Thereto was added R10 medium (a medium added to have final concentrations of 10% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine, 50 μM 2-mercaptoethanol, to RPMI-1640 medium (Sigma); the same composition as the 10% FCS mixing RPMI-1640 medium) so as to be a total amount of 200 μl. Thereafter, the plate was incubated at an incubator at 37° C., 5% CO2, for 24 hours.
In order to observe cell proliferation of lymphocytes by SV40 VP1 VLP stimulation, for a well added with a wt SV40 VP1 VLP solution and a well added with PBS(−) buffer in a flat-bottom plate, the cells were observed under an inverted phase contrast microscope. The cells were observed at ×200. The result is shown in
A well added with a wt SV40 VP1 VLP solution, a well added with PBS(−) buffer and a well with only R10 medium and lymphocytes in the round-bottom plate after incubation for 24 hours described above were spun down at 4° C., 1,400 rpm. The supernatant was removed, and the cells were loosened with a Vortex mixer. Thereafter, FACS buffer (2% FCS, 0.1% sodium azide, 1×PBS(−)) was added at 200 μl/well. The mixture was again spun down at 4° C., 1,400 rpm to remove the supernatant, and the cells were loosened. Thereafter, 100 μl of LEAF Purified Rat Anti-Mouse CD16/32 Clone: 93 (BioLegend) diluted to 20 μg/ml with FACS buffer was added thereto, and the mixture was incubated at 4° C. for 10 minutes. Thereafter, washing operation with 200 μl of FACS buffer was carried out once. 50 μl each of PE Rat Anti-Mouse CD86 Clone: GL-1 (BioLegend) diluted to 10 μg/ml with FACS buffer was added to the loosened cells. The mixture was incubated in a dark place at 4° C. for 30 minutes. Thereafter, washing operation with 200 μl of FACS buffer was carried out twice. Thereafter, FACS fixation buffer (1% formaldehyde, 1×FACS buffer) was added to the loosened cells, at 100 μl per well. The mixture was incubated in a dark place at 4° C. overnight. Thereafter, 400 μl of FACS buffer was added to 5 ml of a polystyrene tube (BD Falcon, 5 ml polystyrene round-bottom tube 12×75 mm style). Thereto was added the sample fixed with 100 μl of FACS fixation buffer. Histogram analysis was performed with FACScan (Becton Dickinson). Cell Quest (Becton Dickinson) software was used for the analysis.
The results are shown in
A CTL epitope sequence (FMP:58-66 epitope (influenza Matrix Protein 58-66 epitope): GILGFVFTL) (this epitope sequence is an epitope sequence for HLA-A*0201 of human MHC class I) of an influenza virus particle internal protein matrix protein 1 (M1) was inserted into SV40 VP1. Specifically, a DE loop region (137 to 138 amino acid region, classically, 4th Ala of a VP1 gene as amino acid No. 1) or an HI loop region (273 to 274 amino acid region) of VP1 was replaced with GILGFVFTL in which three glycines are added at the amino terminal and the carboxyl terminal to prepare a M1 CTL epitope-inserted SV40 VP1 insertion mutant (FMP-DE-VP1, FMP-HIVP1). The mutant was prepared by the Overhang PCR method by employing pFastBac 1-SV40 wild type VP1 encoding SV40 VP1 as a template. The following primers were used.
10 ng of a template was employed. Each 50 pmol of primers was added to prepare 30 μL of a mixed solution containing 2.5 units of a KOD polymerase (TOYOBO), 0.2 mM dNTPs, 1 mM MgCl2, 6 mM (NH4)2SO4, 10 mM KCl, 120 mM Tris-HCl (pH 8.0), 0.1% Triton X-100, and 0.001% BSA.
In PCR, in both of 1st round and 2nd round, after incubation at 98° C. for 60 seconds, the following cycle was repeated 25 times (98° C. for 15 seconds, 59° C. for 15 seconds, 74° C. for 30 seconds) and finally, incubation was performed at 74° C. for 1 minute and 30 seconds, and the procedure was migrated to 4° C.
PCR fragments prepared by the Overhang PCR were cut with restriction enzymes KpnI and SalI. The cut PCR fragments were inserted between KpnI and SalI sites of a pFastBac 1 plasmid vector to obtain FMP-DE-VP1 and FMP-HI-VP1 plasmids. Escherichia coli DH10bac (invitrogen) holding a baculovirus genome was transformed with each plasmid to prepare a recombinant baculovirus genome with the coding sequence of loop region epitope-inserted VP1 incorporated therein. The recombinant baculovirus genome was transfected to Sf-9 cells. After three days, the supernatant thereof was collected to obtain a solution containing recombinant baculovirus. A part of this solution was again infected with Sf-9 cells, thereby increasing a recombinant baculovirus titer. The resulting solution was referred to as a stock solution of a recombinant baculovirus.
A recombinant baculovirus with FMP-DE-VP1 or FMP-HI-VP1 incorporated therein was infected with Sf-9 cells (3×107) were inoculated at a multiplicity of infection of 0.05 to 0.2 (M.O.I. base). Three days after infection, the Sf-9 cells were collected and then washed with PBS(−). Thereafter, the cells were resuspended in 1 ml of buffer for VP1 ultrasonic treatment (20 mM Tris-HCl (pH 7.9), 1% sodium deoxycholate (Sigma), 2 μM phenylmethanesulfonyl fluoride (Sigma), 1 μg/ml chymostatin (Sigma), 1 μg/ml aprotinin (Sigma), 1 μg/ml leupeptin (Sigma), 1 μg/ml antipain (Sigma) and 1 μg/ml pepstatin (Sigma)), and ultrasonic-crushed. Thereafter, the crushed substance was centrifuged at 15,000 rpm, 4° C. for 5 minutes to separate into supernatant and pellet, and the supernatant was removed. To the remaining pellet was added 200 μl of a 50% Opti-prep (trademark) solution (20 mM Tris-HCl (pH 7.9), 50% Opti-prep (trademark)), and the mixture was resuspended by ultrasonication. The resuspension was referred to as a pellet solution (a FMP-DE-VLP solution and a FMP-HI-VLP solution, respectively).
The lymphocytes were prepared from the spleen of mouse as described in Example 1, except for using the spleen of non-immune HHD mouse in place of that of the intraperitoneally immunized mouse.
An Opti-prep buffer, a FMP-DE-VLP solution (500 μg/ml in 20 mM Tris-HCl (pH 7.9) and 50% Opti-prep), and a FMP-HI-VLP solution (500 μg/ml in 20 mM Tris-HCl (pH 7.9) and 50% Opti-prep) were added to a 96-well round-bottom plate at each 5 d/well. Thereto were added 5×105 mouse lymphocytes. The R10 medium was added so as to be a total amount of 200 μl. Thereafter, the plate was incubated at an incubator at 37° C., 5% CO2, for 24 hours.
After incubation, pretreatment of FACScan was performed as described in Example 2, and histogram analysis was performed with FACScan (Becton Dickinson). Cell Quest (Becton Dickinson) software was used for the analysis.
The result is shown in
A baculovirus expressing wt SV40 VP1 was prepared by the same method as described in Example 1.
wt SV40 VP1 VLP was prepared by the same method as described in Example 1.
A baculovirus expressing M1 CTL epitope-inserted SV40 VP1 was prepared by the same method as described in Comparative Example 1.
FMP-DE-VLP and FMP-HI-VLP were prepared by the same method as described in Comparative Example 1.
The lymphocytes were prepared from the spleen of mouse as described in Example 1, except for using the spleen of non-immune HHD mouse in place of that of the intraperitoneally immunized mouse.
A wt SV40 VP1 VLP sample was prepared as follows. To a 96-well round-bottom plate was added a wt SV40 VP1 VLP solution (500 μg/ml in PBS(−)) at 5 μl/well. Thereto were added 5×105 lymphocytes prepared from the spleen of non-immune HHD mouse. The R10 medium was added so as to be a total amount of 200 μl. Thereafter, the plate was incubated at an incubator at 37° C., 5% CO2, for 24 hours.
A GM1-treated wt SV40 VP1 VLP sample and a GD1a-treated wt SV40 VP1 VLP sample were prepared as follows. To a 96-well round-bottom plate was added a wt SV40 VP1 VLP solution (500 μg/ml in PBS(−)) at 5 μl/well. Thereto was added 100 μl of a ganglioside GM1 solution (20 μg/ml in the R10 medium) that is a type of glycolipids, a receptor of SV40, or 100 μl of a ganglioside GD1a solution (20 μg/ml in the R10 medium) that is a type of glycolipids, not a receptor of SV40. The mixture was incubated at 37° C., 5% CO2 incubator, for 1 hour. After incubation, thereto were added 5×105 lymphocytes prepared from the spleen of non-immune HHD mouse. The R10 medium was added so as to be a total amount of 200 μl. Thereafter, the plate was incubated at an incubator at 37° C., 5% CO2, for 24 hours.
To a 96-well round-bottom plate was added PBS(−) at 5 μl/well, as a control. Thereto were added 5×105 lymphocytes prepared from the spleen of non-immune HHD mouse. The R10 medium was added so as to be a total amount of 200 μl. Thereafter, the plate was incubated at an incubator at 37° C., 5% CO2, for 24 hours.
After incubation, pretreatment of FACScan (Becton Dickinson) was performed as described in Example 2, and histogram analysis was performed with FACScan (Becton Dickinson). Cell Quest (Becton Dickinson) software was used for the analysis.
The results are shown in
A FMP-DE-VLP sample and a FMP-HI-VLP sample were prepared as follows. The FMP-DE-VLP solution (500 μg/ml in 20 mM Tris-HCl (pH 7.9) and 50% Opti-prep) prepared in Comparative Example 1, and the FMP-HI-VLP solution (500 μg/ml in 20 mM Tris-HCl (pH 7.9) and 50% Opti-prep) prepared in Comparative Example 1 were added to a 96-well round-bottom plate at each 5 μl/well. Thereto were added 5×105 lymphocytes prepared from the spleen of non-immune HHD mouse. The R10 medium was added so as to be a total amount of 200 μl. Thereafter, the plate was incubated at an incubator at 37° C., 5% CO2, for 24 hours.
A GM1-treated FMP-DE-VLP sample and a GM1-treated FMP-HI-VLP sample were prepared as follows. A FMP-DE-VLP solution (500 μg/ml in 20 mM Tris-HCl (pH 7.9) and 50% Opti-prep), and a FMP-HI-VLP solution (500 μg/ml in 20 mM Tris-HCl (pH 7.9) and 50% Opti-prep) were added to a 96-well round-bottom plate at each 5 μl/well. Thereto was added 100 μl of a ganglioside GM solution (20 μg/ml in the R10 medium) that is a type of glycolipids, a receptor of SV40. The mixture was incubated at 37° C., 5% CO2 incubator, for 1 hour. After incubation, thereto were added 5×105 lymphocytes prepared from the spleen of non-immune HHD mouse. The R10 medium was added so as to be a total amount of 200 μl. Thereafter, the plate was incubated at an incubator at 37° C., 5% CO2, for 24 hours.
To a 96-well round-bottom plate was added a buffer containing 20 mM Tris-HCl (pH 7.9) and 50% Opti-prep at 5 μl/well, as a control. Thereto were added 5×10 lymphocytes prepared from the spleen of non-immune HHD mouse. The R10 medium was added so as to be a total amount of 200 μl. Thereafter, the plate was incubated at an incubator at 37° C., 5% CO2, for 24 hours.
After incubation, pretreatment of FACScan was performed as described in Example 2, and histogram analysis was performed with FACScan (Becton Dickinson). Cell Quest (Becton Dickinson) software was used for the analysis.
The results are shown in
Based on the above, it was considered that the mechanism of expression induction of CD86 molecule does not work through the binding with GM1. Therefore, a possibility different from the mechanism of CD86 expression induction by wt SV40 VP1 VLP was suggested.
A FLAG sequence (DYKDDDDK) or a 3xRGD sequence (RGDRGDRGD) was inserted into SV40 VP1. Specifically, a DE loop region (137 to 138 amino acid region, classically, 4th Ala of a VP1 gene as amino acid No. 1) of VP1 was replaced with DYKDDDDK or RGDRGDRGD in which three glycines are added at the amino terminal and the carboxyl terminal to prepare a FLAG sequence-inserted SV40 VP1 insertion mutant (DE-FLAG VP1) or 3xRGD sequence-inserted SV40 VP1 insertion mutant (DE-3xRGD VP1). The mutant was prepared by the Overhang PCR method by employing pFastBac 1-SV40 wild type VP1 encoding SV40 VP1 as a template.
10 ng of a template was employed. Each 50 pmol of primers were added to prepare 30 μL of a mixed solution containing 2.5 units of a KOD polymerase (TOYOBO), 0.2 mM dNTPs, 1 mM MgCl2, 6 mM (NH4)2SO4, 10 mM KCl, 120 mM Tris-HCl (pH 8.0), 0.1% Triton X-100, and 0.001% BSA.
In PCR, in both of 1st round and 2nd round, after incubation at 98° C. for 60 seconds, the following cycle was repeated 25 times (98° C. for 15 seconds, 59° C. for 15 seconds, 74° C. for 30 seconds) and finally, incubation was performed at 74° C. for 1 minute and 30 seconds, and the procedure was migrated to 4° C.
PCR fragments prepared by the Overhang PCR were cut with restriction enzymes KpnI and SalI. The cut PCR fragments were inserted between KpnI and SalI sites of a pFastBac 1 plasmid vector to obtain DE-FLAG VP1 or DE-3xRGD VP1 plasmid. Escherichia coli DH10bac (invitrogen) holding a baculovirus genome was transformed with each plasmid to prepare a recombinant baculovirus genome with the coding sequence of recombinant VP1 incorporated therein. The recombinant baculovirus genome was transfected to Sf-9 cells. After three days, the supernatant thereof was collected to obtain a solution containing recombinant baculovirus. A part of this solution was again infected with Sf-9 cells, thereby increasing a recombinant baculovirus titer. The resulting solution was referred to as a stock solution of a recombinant baculovirus.
A coding sequence of FLAG tag (SEQ ID No. 18) was added to the upstream of a codon encoding an amino terminus (N-terminus) of wt SV40 VP2 (SEQ ID No. 16; the nucleic acid sequence is shown in SEQ ID No. 17), and a BamHI site was introduced into the further upstream thereof. The stop codon of wt SV40 VP2 coding sequence was removed, and an EcoRI site was introduced. The obtained polynucleotide was inserted via the BamHI site of pFastBac1 plasmid and the EcoRI site to prepare a plasmid containing wt SV40 VP2 gene. A coding sequence of a GGGGSGGGGSGGGGS linker (SEQ ID No. 19; the nucleic acid sequence is shown in SEQ ID No. 20) was introduced into the upstream of a codon encoding an N-terminus of M1 protein, and an EcoRI site was introduced into the further upstream thereof. The stop codon was added to the downstream of M1 protein coding sequence, and a Sal I site was introduced into the further downstream thereof. The obtained polynucleotide was introduced via the EcoRI site of the plasmid containing wt SV40 VP2 gene and the Sal I site to prepare a plasmid holding a gene fused with the M1 coding sequence in the downstream of the VP2 coding sequence.
Escherichia coli DH10bac (invitrogen) holding a baculovirus genome was transformed with this plasmid to prepare a recombinant baculovirus genome expressing protein VP2-M1 in which M1 was fused with wt SV40 VP2 (SEQ ID No. 21; the nucleic acid sequence is shown in SEQ ID No. 22). These recombinant baculovirus genomes were transfected to Sf-9 cells. After three days, the supernatant thereof was collected to obtain a solution containing recombinant baculovirus. A part of this solution obtained above was again infected with Sf-9 cells, thereby increasing a recombinant baculovirus titer. The resulting solution was referred to as a stock solution of a recombinant baculovirus.
A recombinant baculovirus with wt SV40 VP1 incorporated therein (M.O.I. (multiplicity of infection)=0.05 to 0.2) and a baculovirus with VP2-M1 incorporated therein (M.O.I.=0.015 to 0.06) were coinfected in a 15 cm culture dish in which 3×107 Sf-9 cells were inoculated (infection ratio of wt SV40 VP1:VP2-M1=1:0.3 (M.O.I. base)). A total of 10 dishes was prepared. Three days after infection, a total of 3×108 Sf-9 cells inoculated on these 10 dishes were collected, and washed with PBS(−). Thereafter, the cells were resuspended in 10 ml of a buffer for VP1 ultrasonic treatment (20 mM Tris-HCl (pH 7.9), 1% (w/vol) deoxycholic acid (Sigma)). In order to suppress endogenous protease activity, 2 mM phenylmethylsulfonyl fluoride (final concentration of 2 LM, Sigma), chymostatin (final concentration of 1 μg/ml, Sigma), aprotinin (final concentration of 1 g/ml, Sigma), leupeptin (final concentration of 1 g/ml, Sigma), antipain (final concentration of 1 μg/ml, Sigma) and pepstatin (final concentration of 1 μg/ml, Sigma) were added thereto, and the mixture was ultrasonically crushed. Thereafter, the crushed substance was centrifuged at 15,000 rpm, 4° C. for 5 minutes to separate into supernatant and pellet, and the supernatant was defined as a lysate solution.
Each 1.5 ml of a 20% CsCl solution (20 mM Tris-HCl (pH 7.9), 20% (w/vol) cesium chloride), a 30% CsCl solution (20 mM Tris-HCl (pH 7.9), 30% (w/vol) cesium chloride), a 40% CsCl solution (20 mM Tris-HCl (pH 7.9), 40% (w/vol) cesium chloride), and a 50% CsCl solution (20 mM Tris-HCl (pH 7.9), 50% (w/vol) cesium chloride) were superposed in an Ultra-Clear centrifugation tube (14×89 mm, Beckman coulter) in descending order of density, for density gradient centrifugation of cesium chloride. Further, 5 ml of the lysate solution containing wt SV40 VP1 containing VP2-M1 was superposed. The centrifugation tube was ultracentrifuged at 35,000 rpm, 4° C. for 3 hours (SW41Ti rotor, Beckman).
After ultracentrifugation, a white band appeared at the center was collected with 23 G, 1 ml of a Terumo syringe (0.60×32 mm, TERUMO). This fraction was mixed with a 37% CsCl solution (20 mM Tris-HCl (pH 7.9), 37% (w/vol) cesium chloride), and the mixture was transferred to an Ultra-Clear centrifugation tube (11×60 mm, Beckman coulter). Thereafter, the centrifugation tube was ultracentrifuged at 50,000 rpm, 4° C. for 20 hours (SW60Ti rotor, Beckman). After ultracentrifugation, a white band appeared at the center was collected with 23 G, 1 ml of a Terumo syringe (0.60×32 mm, TERUMO). This fraction was dialyzed (Slide-A-Lyzer (trademark) MINI Dialysis Units, 3500 MWCO, Thermo SCIENTIFIC) against a PBS(−) solvent. This fraction was centrifuged at 15,000 rpm, 4° C. for 5 minutes. The supernatant was collected and referred to as a wt SV40 VP1 VLP fraction containing purified VP2-M1.
A recombinant baculovirus with DE-FLAG VP1 or DE-3xRGD VP1 incorporated therein (M.O.I. (multiplicity of infection)=0.05 to 0.2) and a baculovirus with VP2-M1 incorporated therein (M.O.I.=0.015 to 0.06) were coinfected in a 15 cm culture dish in which 3×107 Sf-9 cells were inoculated (infection ratio of DE-FLAG VP1 or DE-3xRGD VP1:VP2-M1=1:0.3 (M.O.I. base)). A total of 10 dishes was prepared. Three days after infection, a total of 3×108 Sf-9 cells inoculated on these 10 dishes were collected, and washed with PBS(−). Thereafter, the cells were resuspended in 10 ml of a buffer for VP1 ultrasonic treatment (20 mM Tris-HCl (pH 7.9), 1% (w/vol) deoxycholic acid (Sigma)). Thereafter, in order to suppress endogenous protease activity, 2 mM phenylmethylsulfonyl fluoride (final concentration of 2 μM, Sigma), chymostatin (final concentration of 1 μg/ml, Sigma), aprotinin (final concentration of 1 μg/ml, Sigma), leupeptin (final concentration of 1 μg/ml, Sigma), antipain (final concentration of 1 μg/ml, Sigma) and pepstatin (final concentration of 1 μg/ml, Sigma) were added thereto, and the mixture was ultrasonically crushed. Thereafter, the crushed substance was centrifuged at 15,000 rpm, 4° C. for 5 minutes to separate into supernatant and pellet, and the supernatant was referred to as a lysate solution.
Each 1.5 ml of a 20% CsCl solution (20 mM Tris-HCl (pH 7.9), 20% (w/vol) cesium chloride), a 30% CsCl solution (20 mM Tris-HCl (pH 7.9), 30% (w/vol) cesium chloride), a 40% CsCl solution (20 mM Tris-HCl (pH 7.9), 40% (w/vol) cesium chloride), and a 50% CsCl solution (20 mM Tris-HCl (pH 7.9), 50% (w/vol) cesium chloride) were superposed in an Ultra-Clear centrifugation tube (14×89 mm, Beckman coulter) in descending order of density, for density gradient centrifugation of cesium chloride. Further, 5 ml of the lysate solution containing wt SV40 VP1 containing VP2-M1 was superposed. The centrifugation tube was ultracentrifuged at 35,000 rpm, 4° C. for 3 hours (SW41Ti rotor, Beckman).
After ultracentrifugation, a white band appeared at the center was collected with 23 G, 1 ml of a Terumo syringe (0.60×32 mm, TERUMO). This fraction was mixed with a 37% CsCl solution (20 mM Tris-HCl (pH 7.9), 37% (w/vol) cesium chloride), and the mixture was transferred to an Ultra-Clear centrifugation tube (11×60 mm, Beckman coulter). Thereafter, the centrifugation tube was ultracentrifuged at 50,000 rpm, 4° C. for 20 hours (SW60Ti rotor, Beckman). After ultracentrifugation, a white band appeared at the center was collected with 23 G, 1 ml of a Terumo syringe (0.60×32 mm, TERUMO). This fraction was dialyzed (Slide-A-Lyzer (trademark) MINI Dialysis Units, 3500 MWCO, Thermo SCIENTIFIC) against a PBS(−) solvent. This fraction was centrifuged at 15,000 rpm, 4° C. for 5 minutes. The supernatant was collected and referred to as a DE-FLAG VP1 VLP fraction containing purified VP2-M1 and a DE-3xRGD VP1 VLP fraction containing purified VP2-M1.
Increase in expression of CD86 molecule by stimulation of wt SV40 VP1 VLP containing VP2-M1, DE-FLAG VLP containing VP2-M1, and DE-3xRGD VLP containing VP2-M1
A wt SV40 VP1 VLP solution containing VP2-M1 (500 μg/ml in PBS(−)), a DE-3xRGD VLP solution containing VP2-M1 (500 μg/ml in PBS(−)) and a DE-FLAG VLP solution containing VP2-M1 (500 μg/ml in PBS(−)) were added to a 96-well round-bottom plate at each 5 μl/well. Thereto were added 5×105 lymphocytes prepared from the spleen of non-immune HHD mouse. The R10 medium was added so as to be a total amount of 200 μl. Thereafter, the plate was incubated at an incubator at 37° C., 5% CO2, for 24 hours.
After incubation, pretreatment of FACScan was performed as described in Example 2, and histogram analysis was performed with FACScan (Becton Dickinson). Cell Quest (Becton Dickinson) software was used for the analysis.
The results are shown in
Based on the above result, it became clear that, when a heterologous peptide is inserted into a loop region of VP1, there may be cases where induction of CD86 molecule is not observed. Thus, it was suggested that wt SV40 VP1 VLP is effective for certainly inducing expression of CD86 molecule (activation of lymphocytes).
A baculovirus expressing wt SV40 VP1 was prepared by the same method as described in Example 1.
wt SV40 VP1 VLP was prepared by the same method as described in Example 1.
The lymphocytes were prepared from the spleen of mouse as described in Example 1, except for using the spleen of non-immune HHD mouse in place of that of the intraperitoneally immunized mouse.
To a 96-well round-bottom plate was added a wt SV40 VP1 VLP solution (500 μg/ml in PBS(−)) or PBS(−) alone at 5 d/well. Thereto were added 5×105 lymphocytes prepared from the spleen of non-immune HHD mouse. The R10 medium was added so as to be a total amount of 200 μl. Thereafter, the plate was incubated at an incubator at 37° C., 5% CO2, for 24 hours.
After incubation, the mixture was spun down at 4° C., 1,400 rpm to remove the supernatant, and the cells were loosened with a Vortex mixer. Thereafter, FACS buffer (2% FCS, 0.1% sodium azide, 1×PBS(−)) was added at 200 μl/well. The mixture was again spun down at 4° C., 1,400 rpm to remove the supernatant, and the cells were loosened. Thereafter, 100 μl of LEAF Purified Rat Anti-Mouse CD16/32 Clone: 93 (BioLegend) diluted to 20 μg/ml with FACS buffer was added thereto, and the mixture was incubated at 4° C. for 10 minutes. After incubation, washing operation with 200 μl of FACS buffer was carried out once. Thereafter, the cells were loosened and treated as follows.
(1) 50 μl of FITC American Hamster Anti-Mouse CD69 Clone: H1.2F3 (BD Pharmingen) diluted to 10 μg/ml with FACS buffer was added to the loosened cells, and the mixture was incubated in a dark place at 4° C. for 30 minutes.
(2) 50 μl of PE Armenian Hamster Anti-Mouse/Rat CD81 Clone: Eat-2 (BioLegend) diluted to 10 μg/ml with FACS buffer was added to the loosened cells, and the mixture was incubated in a dark place at 4° C. for 30 minutes.
(3) 50 μl of PE Rat Anti-Mouse CD83 Clone: Michel-19 (BioLegend) diluted to 10 μg/ml with FACS buffer was added thereto, and the mixture was incubated in a dark place at 4° C. for 30 minutes.
(4) 50 μl of PE Rat Anti-Mouse CD86 Clone: GL-1 (BioLegend) diluted to 10 μg/ml with FACS buffer was added thereto, and the mixture was incubated in a dark place at 4° C. for 30 minutes.
(5) 50 μl of PE Armenian Hamster Anti-Mouse CD196 (CCR6) Clone: 29-2L17 (BioLegend) diluted to 10 μg/ml with FACS buffer was added to the loosened cells, and the mixture was incubated in a dark place at 4° C. for 30 minutes.
(6) 50 μl of PE Rat Anti-Mouse CD197 (CCR7) Clone: 4B12 (BioLegend) diluted to 10 μg/ml with FACS buffer was added thereto, and the mixture was incubated in a dark place at 4° C. for 30 minutes.
After incubation, washing operation with 200 μl of FACS buffer was carried out twice. Thereafter, FACS fixation buffer (1% formaldehyde, 1×FACS buffer) was added to the loosened cells at 100 μl/well. The mixture was incubated in a dark place at 4° C. overnight. Thereafter, 400 μl of FACS buffer was added to 5 ml of a polystyrene tube (BD Falcon, 5 ml polystyrene round-bottom tube 12×75 mm style). Thereto was added a sample fixed with 100 μl of FACS fixation buffer. Thereafter, histogram analysis was performed with FACScan (Becton Dickinson). Cell Quest (Becton Dickinson) software was used for the analysis. The results are shown in
As shown in each figure in the upper row of
To a 96-well round-bottom plate was added a wt SV40 VP1 VLP solution (500 μg/ml in PBS(−)) at 5 μl/well. Thereto were added 5×105 lymphocytes prepared from the spleen of non-immune HHD mouse. The R10 medium was added so as to be a total amount of 200 μl. Thereafter, the plate was incubated at an incubator at 37° C., 5% CO2, for 24 hours.
After incubation, the mixture was spun down at 4° C., 1,400 rpm to remove the supernatant, and the cells were loosened with a Vortex mixer. Thereafter, FACS buffer (2% FCS, 0.1% sodium azide, 1×PBS(−)) was added at 200 μl/well. The mixture was again spun down at 4° C., 1,400 rpm to remove the supernatant, and the cells were loosened. Thereafter, 100 μl of LEAF Purified Rat Anti-Mouse CD16/32 Clone: 93 (BioLegend) diluted to 20 μg/ml with FACS buffer was added thereto, and the mixture was incubated at 4° C. for 10 minutes. After incubation, washing operation with 200 μl of FACS buffer was carried out twice. Thereafter, BD Cytofix/Cytoperm (trademark) (BD Biosciences) was added to the loosened cells at 100 μl/well, and the mixture was incubated in a dark place at 4° C. for 20 minutes. After incubation, the same procedure was carried out twice as the washing operation using the FACS buffer, with 200 μl of 1×BD Perm/Wash (registered trademark) (BD biosciences). Thereafter, 2.5 μL of PE Rat anti-mouse CD63 antibody Clone: NVG-2 (BioLegend) or PE Rat anti-mouse CD68 antibody Clone: FA-11 (BioLegend) was added to 50 μl of 1×BD Perm/Wash (registered trademark). The mixture was added to the loosened cells, and this mixture liquid was added to each well. The mixture was incubated in a dark place at 4° C. for 30 minutes.
After incubation, the washing operation with 200 μl of 1×BD Perm/Wash (trademark) was carried out twice. Thereafter, FACS fixation buffer (1% formaldehyde, 1×FACS buffer) was added to the loosened cells at 100 μl per well, and the mixture was incubated in a dark place at 4° C. overnight. After incubation, 400 μl of FACS buffer was added to 5 ml of a polystyrene tube (BD Falcon, 5 ml polystyrene round-bottom tube 12×75 mm style). Thereto was added a sample fixed with 100 μl of FACS fixation buffer. Thereafter, histogram analysis was performed with FACScan (Becton Dickinson). Cell Quest (Becton Dickinson) software was used for the analysis. The results are shown in
As shown in each figure in the upper row of
A baculovirus expressing wt SV40 VP1 was prepared by the same method as described in Example 1.
wt SV40 VP1 VLP was prepared by the same method as described in Example 1.
The lymphocytes were prepared from the spleen of mouse as described in Example 1, except for using the spleen of non-immune HHD mouse in place of that of the intraperitoneally immunized mouse.
By positive selection from mouse spleen lymphocytes using magnetic beads, CD4+T cells (mouse CD4 (L3T4) MicroBeads (Miltenyi Biotec Inc., 130-049-201)), CD8+T cells (mouse CD8a (Ly-2) MicroBeads (Miltenyi Biotec Inc., 130-049-401)) and B cells (mouse CD19 MicroBeads (Miltenyi Biotec Inc., 130-052-201)) were prepared according to the method as described in the attached manual. The number of the prepared cells was counted, then the cells were used in the following experiment.
To a 96-well round-bottom plate was added a wt SV40 VP1 VLP solution (500 μg/ml in PBS(−)) at 5 μl/well. Thereto were each added 5×105 cells of CD4+T, CD8+T, and B cells. The R10 medium was added so as to be a total amount of 200 μl. Thereafter, the plate was incubated at an incubator at 37° C., 5% CO2, for 24 hours. After incubation, pretreatment of FACScan was performed as described in Example 2, and histogram analysis was performed with FACScan (Becton Dickinson). Cell Quest (Becton Dickinson) software was used for the analysis. The result is shown in
As shown in each figure in the upper row of
A baculovirus expressing wt SV40 VP1 was prepared by the same method as described in Example 1.
wt SV40 VP1 VLP was prepared by the same method as described in Example 1.
The lymphocytes were prepared from the spleen of mouse as described in Example 1, except for using the spleen of non-immune HHD mouse in place of that of the intraperitoneally immunized mouse.
A baculovirus expressing M1 CTL epitope-inserted SV40 VP1 was prepared by the same method as described in Comparative Example 1.
FMP-DE-VLP and FMP-HI-VLP were prepared by the same method as described in Comparative Example 1.
A wt SV40 VP1 VLP solution (final concentration of 12.5 μg/ml), a FMP-DE-VLP solution (final concentration of 12.5 μg/ml), a FMP-HI-VLP solution (final concentration of 12.5 μg/ml), LPS (lipopolysaccharide, Sigma; final concentration of 1 μg/ml) and CT (cholera toxin, Sigma; final concentration of 12.5 g/ml) were each added to a 96-well round-bottom plate. Thereto were added 5×105 lymphocytes prepared from the spleen of non-immune mouse. The R10 medium was added so as to be a total amount of 200 μl. Thereafter, the plate was incubated at an incubator at 37° C., 5% CO2, for 24 hours.
After incubation, the cell supernatant was collected. The amounts of IFN-γ (DY485 Mouse IFN-gamma DuoSet, R&D SYSTEMS), TNF-α (DY410 Mouse TNF-alpha DuoSet, R&D SYSTEMS), IL-6 (DY406 Mouse IL-6 DuoSet, R&D SYSTEMS), IL-1β (DY401 Mouse IL-1 beta/IL-1F2 DuoSet, R&D SYSTEMS), CCL3 (DY450 Mouse CCL3/MPI-1α DuoSet, R&D SYSTEMS) and CCL4 (DY451 Mouse CCL4/MIP-1β DuoSet, R&D SYSTEMS) contained in the cell supernatant were detected by ELISA method. Detection was performed according to the manual of the kit. The result is shown in
As a result, wt SV40 VP1 VLP did not induce secretion of IFN-γ, TNF-α, IL-6 and IL-1β (cytokines inducing systemic inflammation) and induced secretion of CCL3 and CCLA (chemokines inducing local inflammation). On the other hand, CT induced secretion of IL-6 and IL-1β, in addition to CCL3 and CCL4, and LPS induced secretion of all cytokines and chemokines. Based on the above, it was suggested that wt SV40 VP1 VLP of the present example reduces systemic inflammation, as compared to CT and LPS that are known adjuvants.
FMP-DE-VLP and FMP-HI-VLP induced a little secretion of IFN-γ, TNF-α and IL-6, and also induced secretion of CCL3 and CCL4. However, the expression levels of CCL3 and CCL4 were lower than wt SV40 VP1 VLP of the present example. Based on the above, it was suggested that wt SV40 VP1 VLP of the present example reduces systemic inflammation, as compared to FMP-DE-VLP and FMP-HI-VLP, and can further induce local inflammation.
Plasmid pUC-SV40 (SEQ ID No. 24) into which a gene encoding SV40 genome (SEQ ID No. 23) was inserted was treated with BamHI. T4 DNA Ligase (TaKaRa) was added to cyclize the SV40 genome. The cyclized SV40 genome was transfected to CV-1 cells using a transfection reagent (Effectene, Qiagen). Three days after transfection, the medium was collected by the cells. Freezing and melting of the collected medium was repeated three times. Thereafter, the medium was again mixed with CV-1 cells to be infected. Three days after infection, the medium was collected by the cells. The virus titer of the SV40 virus contained in the medium was calculated by the plaque assay method.
The lymphocytes were prepared from the spleen of mouse as described in Example 1, except for using the spleen of non-immune HHD mouse in place of that of the intraperitoneally immunized mouse.
The lymphocytes prepared from the spleen of non-immune mouse were added to a 96-well round-bottom plate at 5×105 cells/well. Thereto was added a SV40 virus solution at 1×106 to 1 plaque forming unit (pfu).
The R10 medium was added so as to be a total amount of 200 μl. Thereafter, the plate was incubated at an incubator at 37° C., 5% CO2, for 24 hours.
After incubation, pretreatment of FACScan was performed as described in Example 2, and histogram analysis was performed with FACScan (Becton Dickinson). Cell Quest (Becton Dickinson) software was used for the analysis.
The results are shown in
On the other hand, the outlined peaks for the mouse lymphocytes stimulated with 1×103 to 1×106 pfu SV40 virus shifted to the right side as compared with the gray peaks (each figure in the upper row of
A SV40 virus solution (1×107 plaque forming unit (pfu)/ml, 1×106 pfu/ml, 1×105 pfu/ml, 1×104 pfu/ml, 1×103 pfu/ml, 1×102 pfu/ml) was added to a 96-well round-bottom plate at 100 μl/well. Thereto were added 5×105 lymphocytes prepared from the spleen of naive mouse. The R10 medium was added so as to be a total amount of 200 μl. Thereafter, the plate was incubated at an incubator at 37° C., 5% CO2, for 24 hours.
After incubation, the cell supernatant was collected. The amounts of IFN-γ (DY485 Mouse IFN-gamma DuoSet, R&D SYSTEMS), TNF-α (DY410 Mouse TNF-alpha DuoSet, R&D SYSTEMS), IL-6 (DY406 Mouse IL-6 DuoSet, R&D SYSTEMS), IL-1β (DY401 Mouse IL-1 beta/IL-1F2 DuoSet, R&D SYSTEMS), CCL3 (DY450 Mouse CCL3/MPI-1α DuoSet, R&D SYSTEMS) and CCL4 (DY451 Mouse CCL4/MIP-1β DuoSet, R&D SYSTEMS) contained in the cell supernatant were detected by ELISA method. Detection was performed according to the manual of the kit. The results are shown in
As a result, the SV40 virus induced secretion of all analyzed cytokines (IFN-γ, TNF-α, IL-6 and IL-1β) and chemokines (CCL3 and CCL4) (
A baculovirus expressing wt SV40 VP1 was prepared as described in Example 1.
wt SV40 VP1 VLP was prepared as described in Example 1.
The lymphocytes were prepared from the spleen of mouse as described in Example 1, except for using the spleen of non-immune HHD mouse in place of that of the intraperitoneally immunized mouse.
Analysis of Phosphorylation of Erk1/2, JNK and p38-MAPK Molecule by Wt SV40 VP1 VLP Stimulation
To a 96-well round-bottom plate was added 5 μl of a wt SV40 VP1 VLP solution (500 μg/ml in PBS(−)) or PBS(−) alone. Thereto were added 5×105 lymphocytes prepared from the spleen of non-immune mouse.
The R10 medium was added so as to be a total amount of 200 μl. Thereafter, the plate was incubated at an incubator at 37° C., 5% CO2, for 10 minutes, 30 minutes, and 1 hour.
After incubation, the mixture was spun down at 4° C., 1,400 rpm to remove the supernatant, and the cells were loosened with a Vortex mixer. Thereafter, FACS buffer (2% FCS, 0.1% sodium azide, 1×PBS(−)) was added at 200 μl/well. The mixture was again spun down at 4° C., 1,400 rpm to remove the supernatant, and the cells were loosened. Thereafter, 100 μl of LEAF Purified Rat Anti-Mouse CD16/32 Clone: 93 (BioLegend) diluted to 20 μg/ml with FACS buffer was added thereto, and the mixture was incubated at 4° C. for 10 minutes. After incubation, washing operation with 200 μl of FACS buffer was carried out twice. Thereafter, BD Cytofix/Cytoperm (registered trademark) (BD Biosciences) was added to the loosened cells at 100 μl/well, and the mixture was incubated in a dark place at 4° C. for 20 minutes. After incubation, the same procedure was carried out twice as the washing operation using the FACS buffer, with 200 μl of 1×BD Perm/Wash (trademark) (BD biosciences). Thereafter, the cells were loosened and treated as follows.
(1) 1 μL of Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP (trademark) Rabbit mAb (PE conjugate) (Cell Signaling TECHNOLOGY, #5682) was added to 50 μl of 1×BD Perm/Wash (registered trademark). This mixture liquid was added to each well, and the resulting mixture was incubated in a dark place at 4° C. for 30 minutes.
(2) 1 μL of Phospho-SAPK/JNK (Thr183/Tyr185) (G9) Mouse mAb (PE Conjugate) (Cell Signaling TECHNOLOGY, #5755) was added to 50 μl of 1×BD Perm/Wash (registered trademark). This mixture liquid was added to each well, and the resulting mixture was incubated in a dark place at 4° C. for 30 minutes.
(3) 1 CL of Phospho-p38 MAPK (Thr180/Tyr182) (3D7) Rabbit mAb (PE Conjugate) (Cell Signaling TECHNOLOGY, #6908) was added to 50 μl of 1×BD Perm/Wash (trademark). This mixture liquid was added to each well, and the resulting mixture was incubated in a dark place at 4° C. for 30 minutes.
After incubation, the washing operation with 200 μl of 1×BD Perm/Wash (trademark) was carried out twice. Thereafter, FACS fixation buffer (1% formaldehyde, 1×FACS buffer) was added to the loosened cells at 100 μl/well. The mixture was incubated in a dark place at 4° C. overnight.
After incubation, 400 μl of FACS buffer was added to 5 ml of a polystyrene tube (BD Falcon, 5 ml polystyrene round-bottom tube 12×75 mm style). Thereto was added a sample fixed with 100 μl of FACS fixation buffer. Thereafter, histogram analysis was performed with FACScan (Becton Dickinson). Cell Quest (Becton Dickinson) software was used for the analysis. The results are shown in
In
As shown in each figure in the upper row of
The cells respond to stimulation of adjuvant or the like and activate, and these molecules are phosphorylated. Phosphorylation of these molecules in lymphocytes suggests that the lymphocytes were activated by wt SV40 VP1 VLP of the present example.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2015-255012 | Dec 2015 | JP | national |
